



## Australian Dementia Network

REGISTRY. CLINICS. TRIALS.

# The Australian Dementia Network

### About us


The Australian Dementia Network (ADNeT) brings together Australia's leading scientists, researchers, and clinicians into the largest national network of experts in Alzheimer's disease and other forms of dementia.

Through our research, we strive to improve the quality of clinical care for people with dementia and mild cognitive impairment. Additionally, we aim to accelerate the development of new therapies for dementia.

The Australian Dementia Network is funded through the Australian Government's Boosting Dementia Research Initiative, with additional support from our philanthropic partners, the Wicking Trust and the Yulgilbar Foundation.

### Our initiatives

Our work is organised around three key initiatives that interact to provide synergies and efficiencies in the way we approach our work and that deliver value and tangible benefits for people living with dementia and their care partners.



## The Australian Dementia Network Screening and Trials Initiative

### Cutting-edge, cost-free specialist diagnostics

The Australian Dementia Network Screening and Trials initiative is creating opportunities for Australians living with dementia to access new therapies under development by attracting major international dementia clinical trials to Australia.

The initiative provides clinicians with cutting-edge specialist diagnostic techniques at *no cost* to the patient, with the aim of facilitating recruitment into intervention trials across Australia.

Eligible patients undergo amyloid PET imaging, MRI, and comprehensive neuropsychological assessment, with a subset also undergoing tau PET and CSF analysis. Results are provided to referring clinicians to assist with diagnosis and management.

### Is my patient eligible?

Eligibility is guided by that of currently recruiting therapy trials. Broadly, patients must meet clinical criteria for MCI or mild AD, or be cognitively normal but at high risk (e.g., first degree family history, e4 carrier, exhibit subtle impairment on clinical examination). In addition, patients must be free of any major concomitant medical or psychiatric illness.

### For referrals, contact:

[ADNET-screening@unimelb.edu.au](mailto:ADNET-screening@unimelb.edu.au)

or in your state:

QLD - [adnet.qld@uq.edu.au](mailto:adnet.qld@uq.edu.au); T. 07 3365 5147

WA - [m.rodriques@ecu.edu.au](mailto:m.rodriques@ecu.edu.au); T. 08 6457 0266

SA - [adnet@sahmri.com](mailto:adnet@sahmri.com); T. 08 8128 4202

NSW, Hunter Region - [participate-sng@newcastle.edu.au](mailto:participate-sng@newcastle.edu.au);  
T. 02 40420 190

NSW, Sydney Region - [adnet.trc@mq.edu.au](mailto:adnet.trc@mq.edu.au); T. 02 9850 2782

VIC - [ADNET-screening@unimelb.edu.au](mailto:ADNET-screening@unimelb.edu.au)

Interested individuals can also register as volunteers for future dementia research and trials via our website

<https://www.australiandementianetwork.org.au/i-am-a-member-of-the-public-or-consumer/volunteer-for-trials/>

For more information, contact Dr Jo Robertson, National ADNeT Screening and Trials Coordinator, at [jo.robertson@unimelb.edu.au](mailto:jo.robertson@unimelb.edu.au) or 0408 508 121